• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    IDEAYA Biosciences (IDYA) Reports Earnings And Shelf Filing, Is The Stock Cheap?

    Simply Wall St·11/07/2026 20:22:46
    Listen to the news

    Why IDEAYA Biosciences Stock Is Back in Focus

    IDEAYA Biosciences (IDYA) moved into the spotlight after third quarter 2026 results showed revenue of US$10.24 million and a swing from profit to net loss, alongside a fresh US$94.92 million shelf registration.

    At a share price of US$31.24, IDEAYA Biosciences has seen its 30 day share price return fall 13.84% and its 90 day move decline 15.61%, even though the 1 year total shareholder return is still up 3.31% and the 5 year total shareholder return sits at 35.65%. This indicates that recent earnings pressure and the new shelf registration have cooled shorter term momentum compared with the longer term record.

    Surf 19 high quality undiscovered gems that, like IDEAYA Biosciences after its earnings and shelf filing, may be under the radar yet already drawing sharper attention from the market.

    Bulls see IDEAYA Biosciences as a long term precision oncology platform on sale after a sharp reset. Bears point to heavy recent losses and fresh equity capacity. Which side does the current valuation lean toward next?

    Most Popular Narrative: 41% Undervalued

    At a last close of $31.24 versus a widely followed fair value of $52.75, the most popular narrative around IDEAYA Biosciences frames the stock as pricing in only part of its oncology franchise, with the rest tied to a series of specific execution milestones.

    The current valuation implies that the market is not fully crediting IDEAYA Biosciences for the potential of darovasertib, the MTAP/CDKN2A/KRAS franchise, the DLL3 Topo-ADC program, and a cash balance of about US$1.24b with a stated runway into 2030.

    See why 1 investors see IDEAYA Biosciences as 41% undervalued.

    Result: Fair Value of $52.75 (UNDERVALUED)

    Still, the narrative around IDEAYA Biosciences could shift quickly if darovasertib faces approval delays or if IDE849 struggles to differentiate in a crowded DLL3 field.

    Find out about the key risks to this IDEAYA Biosciences narrative.

    Another View: When IDEAYA Biosciences Looks Expensive

    The fair value story for IDEAYA Biosciences shifts once the SWS DCF model is brought in. On this framework, IDYA at $31.24 sits above an estimated future cash flow value of $20.16, which screens as overvalued rather than cheap.

    The gap is wide enough that it raises a practical question for investors. Is the market correctly paying up for optionality in the pipeline, or are expectations running ahead of what future cash generation currently supports?

    Look into how the SWS DCF model arrives at its fair value.

    IDYA Discounted Cash Flow as at Nov 2026
    IDYA Discounted Cash Flow as at Nov 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out IDEAYA Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 39 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    Mixed signals around IDEAYA Biosciences can feel messy, so move fast on your own homework and weigh both sides of the story. To see how that balance of concerns and optimism stacks up in one place, review the 1 key reward and 1 important warning sign.

    Looking For More Investment Ideas Beyond IDEAYA Biosciences?

    If IDEAYA Biosciences has sharpened your focus on risk, reward, and timing, broaden your watchlist now so you are not reacting after the next move.